#United States #Paramus #SUDEP Awareness #CURE Epilepsy #Cameron Boyce Foundation

Strengthening SUDEP Awareness Efforts

SK Life Science, Inc., a key player in the U.S. pharmaceutical industry and part of SK Biopharmaceuticals, takes a significant step towards raising awareness about Sudden Unexpected Death in Epilepsy (SUDEP) by engaging in partnerships with noteworthy organizations, namely CURE Epilepsy and The Cameron Boyce Foundation. The initiative coincides with #StopSUDEP Week, scheduled from October 19-23, and extends throughout October, which is dedicated to increasing awareness around epilepsy-related risks.

The cornerstone of SK Life Science's commitment is a matching donation campaign, where the company pledges to match contributions to CURE Epilepsy dollar for dollar up to $10,000. This funding is crucial for amplifying awareness, supporting critical research, and delivering educational resources to families impacted by epilepsy. The campaign aims to confront SUDEP, a serious and frequently overlooked risk associated with epilepsy, which remains a pressing concern within the community.

Through its collaboration with CURE Epilepsy and The Cameron Boyce Foundation, SK Life Science is determined to ensure that individuals living with epilepsy and their families receive crucial information that empowers them to engage confidently with their healthcare providers. Knowledge is indeed power; it enables informed conversations about the management of epilepsy, potentially reducing risks associated with conditions like SUDEP.

During these conversations, those affected are encouraged to consult with healthcare providers regarding medication adherence, recognizing personal seizure triggers, ensuring sufficient sleep, managing alcohol consumption, and implementing appropriate nighttime monitoring measures. These precautions are instrumental in supporting the overall health and well-being of individuals facing epilepsy.

Dr. Sunita Misra, Chief Medical Officer at SK Life Science, emphasized, "Knowledge empowers action, and meaningful conversations can help individuals and families feel more informed and confident in managing epilepsy." Her sentiments are reflected in a recent survey conducted by the company, which unveiled a striking gap: nearly 20% of individuals experiencing daily seizures were either unaware of SUDEP or had not discussed it with their doctor. This disparity highlights the urgent need for enhanced education, awareness, and open dialogues surrounding epilepsy within the healthcare framework.

CURE Epilepsy’s CEO, Beth Lewin Dean, reinforced this critical sentiment, stating, "SUDEP awareness saves lives through knowledge, conversation, and action." She expressed gratitude for SK Life Science’s support, noting that, along with the Cameron Boyce Foundation and the broader epilepsy community, this partnership aims to provide crucial information concerning SUDEP while propelling research forward to prevent future tragedies.

Throughout October, CURE Epilepsy and The Cameron Boyce Foundation spearhead various initiatives designed to uplift SUDEP awareness through education, advocacy, and fundraising efforts. These activities strive to deepen understanding of epilepsy and support ongoing research endeavors intended to address the complexities of SUDEP.

For those wishing to support these initiatives, several resources are available, including the CURE Epilepsy Matching Gift SUDEP Campaign and their dedicated SUDEP Action Day page.

By reaffirming its dedication to the epilepsy community, SK Life Science goes beyond mere medication development; the company recognizes the importance of fostering partnerships that bridge the gaps in education and support for individuals facing epilepsy. They remain committed to advancing research efforts and empowering families grappling with the challenges posed by this condition.

To explore more about SK Life Science’s initiatives aimed at supporting the epilepsy community, visit www.sklifescienceinc.com.

SK Life Science, headquartered in Paramus, New Jersey, is a subsidiary of SK Biopharmaceuticals Co., Ltd., a trailblazer in drug development and commercialization in South Korea. The company focuses on innovating treatments for central nervous system disorders and oncology and has multiple compounds in development, utilizing advanced technologies to enhance research and development processes.